Cargando…

Ex vivo susceptibility and genotyping of Plasmodium falciparum isolates from Pikine, Senegal

BACKGROUND: The monitoring of Plasmodium falciparum sensitivity to anti-malarial drugs is a necessity for effective case management of malaria. This species is characterized by a strong resistance to anti-malarial drugs. In Senegal, the first cases of chloroquine resistance were reported in the Daka...

Descripción completa

Detalles Bibliográficos
Autores principales: Mbaye, Aminata, Gaye, Amy, Dieye, Baba, Ndiaye, Yaye D., Bei, Amy K., Affara, Muna, Deme, Awa B., Yade, Mamadou S., Diongue, Khadim, Ndiaye, Ibrahima M., Ndiaye, Tolla, Sy, Mouhamed, Sy, Ngayo, Koita, Ousmane, Krogstad, Donald J., Volkman, Sarah, Nwakanma, Davis, Ndiaye, Daouda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471902/
https://www.ncbi.nlm.nih.gov/pubmed/28615016
http://dx.doi.org/10.1186/s12936-017-1897-6
_version_ 1783244041032302592
author Mbaye, Aminata
Gaye, Amy
Dieye, Baba
Ndiaye, Yaye D.
Bei, Amy K.
Affara, Muna
Deme, Awa B.
Yade, Mamadou S.
Diongue, Khadim
Ndiaye, Ibrahima M.
Ndiaye, Tolla
Sy, Mouhamed
Sy, Ngayo
Koita, Ousmane
Krogstad, Donald J.
Volkman, Sarah
Nwakanma, Davis
Ndiaye, Daouda
author_facet Mbaye, Aminata
Gaye, Amy
Dieye, Baba
Ndiaye, Yaye D.
Bei, Amy K.
Affara, Muna
Deme, Awa B.
Yade, Mamadou S.
Diongue, Khadim
Ndiaye, Ibrahima M.
Ndiaye, Tolla
Sy, Mouhamed
Sy, Ngayo
Koita, Ousmane
Krogstad, Donald J.
Volkman, Sarah
Nwakanma, Davis
Ndiaye, Daouda
author_sort Mbaye, Aminata
collection PubMed
description BACKGROUND: The monitoring of Plasmodium falciparum sensitivity to anti-malarial drugs is a necessity for effective case management of malaria. This species is characterized by a strong resistance to anti-malarial drugs. In Senegal, the first cases of chloroquine resistance were reported in the Dakar region in 1988 with nearly 7% population prevalence, reaching 47% by 1990. It is in this context that sulfadoxine–pyrimethamine temporarily replaced chloroquine as first line treatment in 2003, pending the introduction of artemisinin-based combination therapy in 2006. The purpose of this study is to assess the ex vivo sensitivity to different anti-malarial drugs of the P. falciparum population from Pikine. METHODS: Fifty-four samples were collected from patients with non-complicated malaria and aged between 2 and 20 years in the Deggo health centre in Pikine in 2014. An assay in which parasites are stained with 4′, 6-di-amidino-2-phenylindole (DAPI), was used to study the ex vivo sensitivity of isolates to chloroquine, amodiaquine, piperaquine, pyrimethamine, and dihydroartemisinin. High resolution melting was used for genotyping of pfdhps, pfdhfr, pfmdr1, and pfcrt genes. RESULTS: The mean IC(50)s of chloroquine, amodiaquine, piperaquine, dihydroartemisinin, and pyrimethamine were, respectively, 39.44, 54.02, 15.28, 2.23, and 64.70 nM. Resistance mutations in pfdhfr gene, in codon 437 of pfdhps gene, and an absence of mutation at position 540 of pfdhps were observed. Mutations in codons K76T of pfcrt and N86Y of pfmdr1 were observed at 51 and 11% population prevalence, respectively. A relationship was found between the K76T and N86Y mutations and ex vivo resistance to chloroquine. CONCLUSION: An increase in sensitivity of isolates to chloroquine was observed. A high sensitivity to dihydroartemisinin was observed; whereas, a decrease in sensitivity to pyrimethamine was observed in the parasite population from Pikine.
format Online
Article
Text
id pubmed-5471902
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54719022017-06-19 Ex vivo susceptibility and genotyping of Plasmodium falciparum isolates from Pikine, Senegal Mbaye, Aminata Gaye, Amy Dieye, Baba Ndiaye, Yaye D. Bei, Amy K. Affara, Muna Deme, Awa B. Yade, Mamadou S. Diongue, Khadim Ndiaye, Ibrahima M. Ndiaye, Tolla Sy, Mouhamed Sy, Ngayo Koita, Ousmane Krogstad, Donald J. Volkman, Sarah Nwakanma, Davis Ndiaye, Daouda Malar J Research BACKGROUND: The monitoring of Plasmodium falciparum sensitivity to anti-malarial drugs is a necessity for effective case management of malaria. This species is characterized by a strong resistance to anti-malarial drugs. In Senegal, the first cases of chloroquine resistance were reported in the Dakar region in 1988 with nearly 7% population prevalence, reaching 47% by 1990. It is in this context that sulfadoxine–pyrimethamine temporarily replaced chloroquine as first line treatment in 2003, pending the introduction of artemisinin-based combination therapy in 2006. The purpose of this study is to assess the ex vivo sensitivity to different anti-malarial drugs of the P. falciparum population from Pikine. METHODS: Fifty-four samples were collected from patients with non-complicated malaria and aged between 2 and 20 years in the Deggo health centre in Pikine in 2014. An assay in which parasites are stained with 4′, 6-di-amidino-2-phenylindole (DAPI), was used to study the ex vivo sensitivity of isolates to chloroquine, amodiaquine, piperaquine, pyrimethamine, and dihydroartemisinin. High resolution melting was used for genotyping of pfdhps, pfdhfr, pfmdr1, and pfcrt genes. RESULTS: The mean IC(50)s of chloroquine, amodiaquine, piperaquine, dihydroartemisinin, and pyrimethamine were, respectively, 39.44, 54.02, 15.28, 2.23, and 64.70 nM. Resistance mutations in pfdhfr gene, in codon 437 of pfdhps gene, and an absence of mutation at position 540 of pfdhps were observed. Mutations in codons K76T of pfcrt and N86Y of pfmdr1 were observed at 51 and 11% population prevalence, respectively. A relationship was found between the K76T and N86Y mutations and ex vivo resistance to chloroquine. CONCLUSION: An increase in sensitivity of isolates to chloroquine was observed. A high sensitivity to dihydroartemisinin was observed; whereas, a decrease in sensitivity to pyrimethamine was observed in the parasite population from Pikine. BioMed Central 2017-06-14 /pmc/articles/PMC5471902/ /pubmed/28615016 http://dx.doi.org/10.1186/s12936-017-1897-6 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Mbaye, Aminata
Gaye, Amy
Dieye, Baba
Ndiaye, Yaye D.
Bei, Amy K.
Affara, Muna
Deme, Awa B.
Yade, Mamadou S.
Diongue, Khadim
Ndiaye, Ibrahima M.
Ndiaye, Tolla
Sy, Mouhamed
Sy, Ngayo
Koita, Ousmane
Krogstad, Donald J.
Volkman, Sarah
Nwakanma, Davis
Ndiaye, Daouda
Ex vivo susceptibility and genotyping of Plasmodium falciparum isolates from Pikine, Senegal
title Ex vivo susceptibility and genotyping of Plasmodium falciparum isolates from Pikine, Senegal
title_full Ex vivo susceptibility and genotyping of Plasmodium falciparum isolates from Pikine, Senegal
title_fullStr Ex vivo susceptibility and genotyping of Plasmodium falciparum isolates from Pikine, Senegal
title_full_unstemmed Ex vivo susceptibility and genotyping of Plasmodium falciparum isolates from Pikine, Senegal
title_short Ex vivo susceptibility and genotyping of Plasmodium falciparum isolates from Pikine, Senegal
title_sort ex vivo susceptibility and genotyping of plasmodium falciparum isolates from pikine, senegal
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471902/
https://www.ncbi.nlm.nih.gov/pubmed/28615016
http://dx.doi.org/10.1186/s12936-017-1897-6
work_keys_str_mv AT mbayeaminata exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal
AT gayeamy exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal
AT dieyebaba exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal
AT ndiayeyayed exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal
AT beiamyk exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal
AT affaramuna exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal
AT demeawab exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal
AT yademamadous exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal
AT dionguekhadim exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal
AT ndiayeibrahimam exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal
AT ndiayetolla exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal
AT symouhamed exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal
AT syngayo exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal
AT koitaousmane exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal
AT krogstaddonaldj exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal
AT volkmansarah exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal
AT nwakanmadavis exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal
AT ndiayedaouda exvivosusceptibilityandgenotypingofplasmodiumfalciparumisolatesfrompikinesenegal